AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 71 min read$DRTS

Levy Raphi sold $32K of DRTS

Levy Raphi (Chief Financial Officer) sold 2,270 shares of Alpha Tau Medical Ltd. (DRTS) at $14.00 on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Levy Raphi
Published Jul 7, 2026, 11:49 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DRTS
Neutral
medium confidence
Mentioned
$DRTS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DRTSNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the pre-arranged nature reduces the signal strength versus discretionary selling.

02

Market read

A modest CFO sale under a 10b5-1 plan is disclosed; likely limited incremental trading signal.

03

What to watch

Insider sales can be misread without context (plan size, prior sales cadence, and whether other insiders also sold/bought around the same window).

Relevance 2/10Novelty 3/10Timing: Filed on 2026-07-07 after the 2026-07-06 sale; relevant for same-day sentiment/positioning checks.

Background

The filing is an SEC Form 4 insider transaction by the company’s CFO, reported as an open-market sale.

Company-level read

Ticker impact

$DRTSNeutralMedium confidence
Context

CFO Levy Raphi filed a Form 4 selling 2,270 shares of Alpha Tau Medical (DRTS) for about $31.8K under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and sentiment-driven.

Evidence & confidence

The transaction is an open-market sale by an officer, explicitly under a Rule 10b5-1 plan, with modest dollar value relative to typical market moves.

Market effects

Sector

No sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Alpha Tau Medical Ltd.

    Subject of the Form 4 insider transaction; ticker DRTS.

  • insider
    Levy Raphi

    Chief Financial Officer who sold 2,270 shares under a Rule 10b5-1 plan.

Read at source← All news

Related articles

JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min